about
Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies.A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A.Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats.Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies.Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration.Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity.Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice.Pharmacological bypass of NAD salvage pathway protects neurons from chemotherapy-induced degenerationA randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effectsMaternal Nicotinamide Riboside Enhances Postpartum Weight Loss, Juvenile Offspring Development, and Neurogenesis of Adult OffspringNicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory SignaturesPPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in gliomaCoronavirus and PARP expression dysregulate the NAD Metabolome: a potentially actionable component of innate immunity
P50
Q33437772-80BA2764-DE28-44D7-98E1-359F45C17809Q34350014-C36C0E2A-F23F-49C0-9F0E-6B9308DE1034Q37336045-8939D344-8B4E-4FB9-9AC6-4E770D4030EFQ39157866-9648B859-007F-40A1-B24D-E0D080E45C6FQ39437234-67BA9C78-D8C0-41AC-9922-A86787B7650AQ40134519-6499A6D0-EA76-4589-A172-1D777DFDC40CQ48139519-56094B39-E72A-44D8-B6E8-FEF173A84B48Q51015762-031B8897-0329-4293-989A-8238D4734214Q51765157-7441501C-00FA-47DC-96E7-ECAF634E1F14Q57460099-B1B0EE05-EDB2-4B74-8118-CEDFD62CC38AQ57734346-3DFE6E36-6929-410E-A36E-1220E8E075BAQ91181577-FB5B6893-975E-42D8-82C8-8F9D947205B0Q92617562-8D885A6E-4710-4251-90B7-36A354D7B701Q92797275-F1541148-9ADB-4A65-AA92-0472B685E744Q95605168-DCC2F065-2B6D-42BC-A48E-9769E87BCAB2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Mark S Schmidt
@en
Mark S Schmidt
@nl
type
label
Mark S Schmidt
@en
Mark S Schmidt
@nl
prefLabel
Mark S Schmidt
@en
Mark S Schmidt
@nl
P31
P496
0000-0003-4593-4096